Pazopanib in relapsed osteosarcoma patients: report on 15 cases
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Osteosarcoma is a rare bone tumor that occurs in young adults with a subsequent peak in the fifth decade. Neoadjuvant and adjuvant chemotherapy and surgery cure approximately 60% of patients with l...
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393 · cited 2×
“[2] Langberg MK, Berglund-Nord C, Cohn-Cedermark G, et al.”
BackgroundGrignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359
Self-citationBacci, G., Briccoli, A., Longhi, A., Ferrari, S., Mercuri, M., Faggioli, F., Versari, M., & Picci, P. (2005) · Acta Oncologica · doi:10.1080/02841860500327503 · Cited by 134
Self-citation
Cited by
The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem
Corre, I., Verrecchia, F., Crenn, V., Redini, F., & Trichet, V. (2020) · Cells · doi:10.3390/cells9040976 · Cited by 474
Molecular Biology of Osteosarcoma
Czarnecka, A. M., Synoradzki, K., Firlej, W., Bartnik, E., Sobczuk, P., Fiedorowicz, M., Grieb, P., & Rutkowski, P. (2020) · Cancers · doi:10.3390/cancers12082130 · Cited by 336
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02374 · Cited by 268
“A case series of 15 patients treated with pazopanib reported one PR (7%) andmedian PFS of 6months.(9) A single-arm phase II trial of sorafenib achieved 4-month PFS of 46%, median PFS of 4 months, and 8% PR rate (three of 35 patients).”
BackgroundSuehara, Y., Alex, D., Bowman, A., Middha, S., Zehir, A., Chakravarty, D., Wang, L., Jour, G., Nafa, K., Hayashi, T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4032 · Cited by 135
“In the present study, the findings of recurrent gene amplifications of CDK4, MDM2, KIT, PDGFRA, KDR, and VEGFA raise the possibility of anumbrella protocol using targeted therapeutics in distinct subsets of patients with osteosarcoma (Fig.”
BackgroundInfluentialPembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Boye, K., Longhi, A., Guren, T., Lorenz, S., Næss, S., Pierini, M., Taksdal, I., Lobmaier, I., Cesari, M., Paioli, A., et al. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-02876-w · Cited by 112
Self-citation
Metadata
- Authors
- Longhi, A., Paioli, A., Palmerini, E., Cesari, M., Abate, M. E., Setola, E., Spinnato, P., Donati, D., Hompland, I., & Boye, K.
- Venue
- Acta Oncologica
- Published
- 2018-09-12
- Volume
- 58
- Issue
- 1
- Pages
- 124-128
- ISSN
- 0284-186X (ISSN-L)
- 1651-226X
- OpenAlex
- W2890746729
- Cited by
- 65
- References
- 3
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pazopanib in relapsed osteosarcoma patients: report on 15 cases. https://app.cochat.ai/papers/10.1080/0284186x.2018.1503714
- The paper
- Longhi, A., Paioli, A., Palmerini, E., Cesari, M., Abate, M. E., Setola, E., Spinnato, P., Donati, D., Hompland, I., & Boye, K. (2019). Pazopanib in relapsed osteosarcoma patients: report on 15 cases. Acta Oncologica. https://doi.org/10.1080/0284186x.2018.1503714
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.